Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs LY 3303560 (Primary) ; LY 3303560 (Primary) ; Florbetapir F 18; Flortaucipir-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly
- 06 Jul 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2018 Planned End Date changed from 1 May 2019 to 1 Jun 2019.